Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from…
Continue Reading-
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
Press Release 02.2020: Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis…
Continue Reading -
MSD to Acquire Themis
Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis…
Continue Reading -
NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a…
Continue Reading -
Themis and Institut Pasteur Join Coronavirus Vaccine Hunt
The Austrian biotech Themis — specializing in vaccines for infectious and insect-borne diseases — has…
Continue Reading -
Hadean Ventures receives Rising Star Award at the 10th edition of the Private Equity Exchange & Awards 2019 in Paris
Paris – Today Hadean Ventures won the Rising Star Award at the 10th edition of…
Continue Reading -
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round
Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round Investment Q2…
Continue Reading
